A common BPC-157 reconstitution is a 5 mg vial in 2 mL of bacteriostatic water, which gives a concentration of 2.5 mg per mL (or 2500 mcg per mL). Research-context dosing typically lands in the 250 to 500 mcg range per administration, given subcutaneously, often near the injury or area of interest. At a 2.5 mg per mL concentration, 250 mcg is 0.10 mL (10 units on a U-100 insulin syringe) and 500 mcg is 0.20 mL (20 units).
Reconstitute 5 mg of BPC-157 in 2 mL of BAC water. Draw 10 units for a 250 mcg dose or 20 units for a 500 mcg dose on a 0.3 or 0.5 mL insulin syringe. Inject subcutaneously, near the site of interest when feasible. Typical frequency is once or twice daily. Typical cycle is 4 to 6 weeks. None of these numbers are FDA-approved dosing guidance because BPC-157 is not an approved drug. They are the research and protocol conventions used in the literature and in research-context user reports.
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found in human gastric juice. It has been studied since the early 1990s, primarily in animal models, for effects on soft tissue repair, tendon and ligament healing, gut lining integrity, and modulation of the inflammatory response. The published literature is largely preclinical (rats, mice, ex-vivo tissue). Human clinical trials are very limited.
BPC-157 is not approved by the FDA for human use. It is sold widely as a research chemical. The peptide itself has a well-characterized chemical structure and supplier-to-supplier variation is mostly in purity rather than identity. See the BPC-157 reference page for the full pharmacology summary.
The standard reconstitution math applies. Concentration in mg per mL equals peptide mass divided by BAC water volume. The conventional choices for a 5 mg BPC-157 vial:
For a 10 mg vial, halve the concentration at any given diluent volume. 10 mg in 2 mL is 5 mg per mL. 10 mg in 4 mL is 2.5 mg per mL and matches the common 5 mg vial setup. The reconstitution calculator handles arbitrary vial sizes and diluent volumes.
The diluent choice is bacteriostatic water for any vial intended to be used over more than a single session, which is essentially every BPC-157 protocol.
The commonly cited dosing range in the research literature is 1 to 10 mcg per kilogram of body weight per administration. For an 80 kg user this works out to 80 to 800 mcg per administration. Most users land at 250 to 500 mcg per administration as a practical middle.
Frequency is typically once or twice daily. Twice-daily dosing (morning and evening) is more common for active injury or pain. Once-daily dosing is more common for general recovery support or systemic effects. Some protocols use a higher single dose (500 to 1000 mcg) once daily; others use a lower split dose (200 to 300 mcg) twice daily. The total daily exposure is similar.
| Use case | Typical dose per administration | Frequency |
|---|---|---|
| Acute soft tissue (tendon, ligament) | 250-500 mcg | Twice daily |
| General recovery support | 250 mcg | Once daily |
| Gut lining (oral capsule format) | 500 mcg | Once daily |
| Stacked with TB-500 | 250-500 mcg of each | Once daily, alternating days |
The most-studied route for BPC-157 in human research-context protocols is subcutaneous injection close to the area of interest. The reasoning, drawn from the preclinical literature, is that local concentration at the target tissue is higher when the injection site is local. For a hamstring issue, the injection goes into the subcutaneous fat over the hamstring. For an Achilles issue, the calf or near the heel. For a wrist or elbow, the soft tissue adjacent to the joint.
Systemic effects do not require local injection. Subcutaneous injection into the abdomen (the conventional GLP-1 injection site) reaches the same systemic circulation and produces systemic exposure. For users dosing for gut effects, broader recovery, or for whom local injection is not practical, abdominal subQ is fine.
Some protocols use oral BPC-157 capsules, particularly for gut-related applications. Oral bioavailability for BPC-157 is debated. The peptide is reported in some sources to be more stable in the gastric environment than typical peptides, which is the rationale for oral dosing, but the systemic bioavailability after oral administration is much lower than after subcutaneous injection. For non-gut applications, subcutaneous is the standard.
BPC-157 has a relatively short plasma half-life after subcutaneous administration, on the order of a few hours by most published estimates. That short half-life is why dosing is typically split into once or twice daily administration rather than weekly. Persistent local exposure at the target tissue, repeated over weeks, is the proposed mechanism in the literature.
This is a meaningful contrast with the GLP-1 class. Semaglutide and tirzepatide are dosed weekly because of their multi-day half-lives. BPC-157 is dosed daily because of its multi-hour half-life. Same peptide category, completely different pharmacokinetic profile.
The typical cycle is 4 to 6 weeks of dosing for an acute injury or recovery focus, followed by a break of 4 to 8 weeks. Some users run longer continuous cycles (8 to 12 weeks) for chronic issues. The published literature does not establish a clear duration limit, in part because there are very few long-term human studies.
Stacked use with TB-500 (thymosin beta-4 fragment) is common in the soft tissue recovery context. The two peptides are typically alternated by day or by week rather than co-administered in the same syringe. See the TB-500 reference page for the comparable reconstitution and dosing math.
BPC-157 is typically reconstituted at 2.5 mg per mL (5 mg vial in 2 mL of BAC water) and dosed at 250 to 500 mcg subcutaneously, once or twice daily, often local to the area of interest, in cycles of 4 to 6 weeks. The math: concentration 2.5 mg per mL, 250 mcg dose equals 0.10 mL equals 10 units on a U-100 syringe. BPC-157 is not FDA-approved. The dosing convention comes from the preclinical literature and from research-context user reports, not from human clinical trials.
For deeper background, the published BPC-157 literature is searchable at PubMed. For the calculator, see the reconstitution calculator.
Peptide AI Stack Intelligence logs the dose, the injection site, the daily function score, and the cycle position. Free on iOS and Android.